Conference

New insight into the physiological activities of Amyloid Beta monomers.

Stefania Zimbone,[a,*] Irene Monaco,[a] Fiorenza Gianì,[a,b] Giuseppe Pandini,[b] Agata G. Copani,[a,c] Maria Laura Giuffrida,[a] Enrico Rizzarelli.[a,d]

Alzheimer's disease (AD) is one of the most common form of dementia in the elderly, characterized by a progressive neurodegeneration associated with synaptic dysfunction, pathological accumulation of β-amyloid (Aβ) in plaques, and neuronal loss. The self-association of Aβ monomers into soluble oligomers seems to be crucial for the development of neurotoxicity.[1]

Some of the toxic effects of Aβ are mediated by its adverse effect on neurotrophic factor expressions. In particular, Aβ oligomers have been found to decrease both phosphorylated CREB and BDNF mRNA in the neuroblastoma cell line, SH-SY5Y, suggesting that oligomeric Aβ could compromise neuronal functions in AD by downregulating BDNF.[2] Accordingly, phosphorylated CREB and CREB-regulated BDNF are recently shown to be reduced in the brain of AD patients and Tg2576 mice.[3]

We previously reported a neuroprotective activity of monomeric Aβ involving the activation of a PI3K/Akt survival pathway.[4] Here we demonstrate that Aβ monomers are specifically able to activate CREB, a converging point for mechanisms and pathways involved in memory formation.[5] Our data suggest a new model whereby Aβ monomers may preserve cognitive decline.

References

1 D. M. Walsh, D. J. Selkoe, Aβ Oligomers – a decade of discovery, Journal of Neurochemistry 101 (5) (2007) 1172–1184. doi:10.1111/j.1471-4159.2006.04426.x.

2 D. J. Garzon, M. Fahnestock, Oligomeric Amyloid Decreases Basal Levels of Brain-Derived Neurotrophic factor (BDNF) mRNA via Specific Downregulation of BDNF Transcripts IV and V in Differentiated Human Neuroblastoma Cells, Journal of Neuroscience 27 (10) (2007) 2628–2635. doi:10.1523/JNEUROSCI.5053-06.2007.

3 S. Pugazhenthi, M. Wang, S. Pham, C.-I. Sze, C. B. Eckman, Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons, Molecular neurodegeneration 6 (1) (2011) 60. doi:10.1186/1750-1326-6-60.

4 M. L. Giuffrida, F. Caraci, B. Pignataro, S. Cataldo, P. De Bona, V. Bruno, G. Molinaro, G. Pappalardo, A. Messina, A. Palmigiano, D. Garozzo, F. Nicoletti, E. Rizzarelli, A. Copani, β-Amyloid Monomers Are Neuroprotective, Journal of Neuroscience 29 (34) (2009) 10582–10587. doi:10.1523/JNEUROSCI.1736-09.2009.

5 A. F. Teich, R. E. Nicholls, D. Puzzo, J. Fiorito, R. Purgatorio, O. Arancio, Synaptic therapy in Alzheimer's disease: a CREB-centric approach, Neurotherapeutics 12 (1) (2015) 29–41. doi:10.1007/s13311-014-0327-5.

[a] *CNR - Istituto di Cristallografia, Via Paolo Gaifami 18, 95126 Catania, Italy.*
[b] *Endocrinology, Department of Clinical and Experimental Medicine, Garibaldi-Nesima Medical Center, University of Catania, via Palermo 636, 95122 Catania, Italy.*
[c] *Department of Drug Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.*
[d] Department of Chemical Sciences, University of Catania, Viale A. Doria 6,95125 Catania, Italy.

† oral communication at 1 st Conference on Crystallography, Structural Chemistry and Biosystems, (Catania) 04-06/10/2021